立方制药股价涨5.37%，景顺长城基金旗下1只基金位居十大流通股东，持有91.01万股浮盈赚取131.96万元

Group 1 - The core viewpoint of the news is that Lifan Pharmaceutical's stock has increased by 5.37%, reaching a price of 28.46 CNY per share, with a total market capitalization of 5.413 billion CNY as of the report date [1] - Lifan Pharmaceutical, established on July 16, 2002, and listed on December 15, 2020, is primarily engaged in the research, production, and sales of pharmaceutical formulations and raw materials, with 97.50% of its revenue coming from pharmaceutical products [1] - The company has a trading volume of 91.038 million CNY and a turnover rate of 2.38% [1] Group 2 - In the context of major shareholders, Invesco Great Wall Fund's healthcare mixed fund has entered the top ten circulating shareholders of Lifan Pharmaceutical, holding 910,100 shares, which is 0.66% of the circulating shares [2] - The Invesco Great Wall Healthcare Mixed A Fund (011876) has achieved a year-to-date return of 28.64% and a one-year return of 24.58%, ranking 3331 out of 8154 and 3709 out of 8046 in its category, respectively [2] - The fund was established on August 18, 2021, and has a current scale of 368 million CNY, with an estimated floating profit of approximately 1.3196 million CNY from its investment in Lifan Pharmaceutical [2]